Scorpius Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCPX research report →
Price Chart
About the company
Scorpius Holdings, Inc. , through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.
- CEO
- Jeff A. Wolf
- IPO
- 2013
- Employees
- 91
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on SCPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.39K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.95
- Div Yield
- 0.00%
- Gross Margin
- -4.09%
- Op Margin
- -893.90%
- Net Margin
- -580.67%
- ROE
- 0.00%
- ROIC
- 2749405.59%
Latest fiscal year · YoY change
- Revenue
- $6.24M-10.7%
- Gross Profit
- $3.05M+237.5%
- Op Income
- $-33,600,261
- Net Income
- $-32,807,843+27.4%
- EPS
- $-13.04+96.2%
- OCF Growth
- +17.5%
- FCF Growth
- +19.8%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -5.33
- RSI (14)
- 47
- Avg Volume
- 5.60K
No earnings-call transcripts are available for SCPX yet.
- Free Float
- 97.4%
- Shares Outstanding
- 12.39M
- Float Shares
- 12.06M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 3, 25 | Thuan Tan Sze | other | 0 |
| May 16, 24 | Wolf Jeffrey Alan | other | 2,500,000 |
| May 16, 24 | Wolf Jeffrey Alan | other | 2,500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCPX coverage
Recent articles, reports, and earnings notes.
No research on SCPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCPX report →Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
businesswire.com · May 14
Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia
globenewswire.com · May 4
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
globenewswire.com · Apr 30
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
globenewswire.com · Apr 21
Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives
globenewswire.com · Feb 26
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™
globenewswire.com · Jan 22
Scorpius Holdings Cancels Planned Reverse Stock Split
globenewswire.com · Jan 17
Scorpius Holdings Announces Reverse Stock Split
globenewswire.com · Jan 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.